Pfizer

PFEApproved

New York, United Statespfizer.com

Founded in 1849, Pfizer has evolved into a global biopharmaceutical leader with a comprehensive portfolio spanning vaccines, oncology treatments, and medicines for chronic diseases. The company operates extensive R&D programs across four key therapeutic areas and maintains a robust clinical pipeline with programs in all phases of development. Led by CEO Albert Bourla, Pfizer continues to drive innovation through strategic partnerships and significant investments in breakthrough science.

Market Cap

$153.4B

Employees

75,000-85,000

Focus

AntibodiesBiologicsBiosimilars

PFE · Stock Price

USD 26.9725.81 (-48.90%)

Historical price data

AI Company Overview

Technology Platform

Pfizer operates a comprehensive biopharmaceutical platform encompassing small molecules, biologics, and mRNA technologies with advanced manufacturing capabilities and global regulatory expertise.

Pipeline Snapshot

1000

1000 drugs in pipeline, 370 in Phase 3

Drug	Indication	Stage
Levonorgestrel/Ethinyl Estradiol	Premenstrual Syndrome	Phase 3
13-valent pneumococcal conjugate vaccine + 7 valent pneumococcal conjugate vacci...	Vaccines, Pneumococcal	Phase 3
Avelumab + Lorlatanib + Talazoparib + Pemetrexed + Axitinib + CMP 001 + Utomilum...	Advanced Malignancies	Phase 3
Maraviroc + Emtricitabine/tenofovir + darunavir/ritonavir 800/100 mg + placebo f...	HIV-1	Phase 3
Ritlecitinib 100 mg + Ritlecitinib 50 mg + Placebo - 100 mg + Placebo - 50 mg	Alopecia Areata	Phase 3

FDA Approved Drugs

102

HYMPAVZIBLAOct 11, 2024

TALZENNANDAMar 7, 2024

VELSIPITYNDAOct 12, 2023

Opportunities

Pfizer is well-positioned to capitalize on the expanding obesity market, leverage its mRNA platform for new vaccines, and continue oncology innovation.

The company's global infrastructure and financial resources enable strategic acquisitions and partnerships to drive growth.

Risk Factors

Key risks include patent cliff pressures from major product expirations, intense competitive dynamics in core therapeutic areas, and ongoing pricing pressures from payers globally.

Regulatory challenges and clinical trial failures could impact pipeline advancement.

Competitive Landscape

Pfizer competes with pharmaceutical giants like J&J, Roche, and Merck across multiple therapeutic areas. The company differentiates through its global scale, manufacturing expertise, and comprehensive portfolio spanning vaccines, oncology, and chronic disease treatments.

Publications

Patents

Pipeline

1000

FDA Approvals

102